^
    Back
    Association details:
    Biomarker:EGFR mutation + RPS6KB1 amplification
    Cancer:Lung Adenocarcinoma
    Drug Class:EGFR inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancer Res Treat
    Title:

    Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma

    Published date:
    07/24/2023
    Excerpt:
    Out of the initial cohort of 257 patients with completely resected stage I EGFR-mutant lung adenocarcinoma, tumor samples from 105 patients were subjected to analysis using large-panel next-generation sequencing….Moreover, RPS6KB1 or EGFR amplifications were linked to a poorer RFS.
    DOI:
    https://doi.org/10.4143/crt.2023.728